ONCOLOGY journal

ONCOLOGY has been in publication for more than 30 years, earning a strong reputation as a reliable source of precise and high-quality information in this fast-changing field. Released every month, ONCOLOGY features reviews of the latest literature and treatment standards. It also includes sections such as: - Clinical Quandaries - How An Expert Approaches It - Comorbidity Consult - Point/Counterpoint

International, Trade/B2B

English

Journal

Outlet metrics

Domain Authority

Ranking

Global

#312172

United States

#144835

Health/Health

#2863

Traffic sources

Monthly visitors

Articles

Radioligand Therapy Retreatment Shows Promise in Metastatic CRPC

6 days ago | cancernetwork.com | Tim Cortese

Retreatment with [177Lu]Lu-PSMA-617 (Pluvicto) showed that it may offer clinical benefit and was well tolerated in a small cohort of patients with metastatic castration-resistant prostate cancer (CRPC) who had sustained prostate-specific membrane antigen (PSMA) expression, according to results from a retrospective single-center study shared at the 2025 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.1 Previously, in March 2022, [177Lu]Lu-PSMA-617 was approved for adult...
Aspirin Does Not Limit Recurrence, Improve Survival in CRC Liver Metastases

1 week ago | cancernetwork.com | Tim Cortese

Adjuvant aspirin did not reduce the rate of recurrence nor improve survival outcomes for patients with colorectal cancer (CRC) liver metastases and cannot be recommended as an adjuvant treatment, according to results from the randomized phase 3 ASAC trial (NCT03326791).1 These findings were shared at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
Mezigdomide Regimens Show Promise in Pretreated R/R Multiple Myeloma

1 week ago | cancernetwork.com | Tim Cortese

Mezigdomide (Mezi) plus dexamethasone and bortezomib (Velcade; MeziVd) or carfilzomib (Kyprolis; MeziKd) demonstrated promising efficacy and a manageable safety profile across all dose levels in patients with relapsed or refractory multiple myeloma, as shown in the results of the phase 1/2 CC-92480-MM-002 trial (NCT03989414) shared at the European Hematology Association 2025 Congress.
First-Line Radiotherapy Combo May Show Benefit in Oligoprogressive HCC

1 week ago | cancernetwork.com | Tim Cortese

First-line systemic therapy plus radiation therapy for oligoprogressive lesions (m-FLST + RT) may offer clinical benefit without the need for second-line systemic therapy with or without radiation therapy (s-SLST + RT) in the treatment of patients with oligoprogressive hepatocellular carcinoma (HCC), according to results from a study published in the International Journal of Radiation Oncology, Biology, and Physics.
FDA Approves Tafasitamab Combo in R/R Follicular Lymphoma

1 week ago | cancernetwork.com | Tim Cortese

The FDA has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide (Revlimid) and rituximab (Rituxan) as a treatment for patients with relapsed or refractory follicular lymphoma, according to a release from the agency.1Supporting results from the double-blind, placebo-controlled phase 3 inMIND trial (NCT04680052) compared the approved combination vs placebo with lenalidomide and rituximab.
LYL314 Yields High, Durable Response Rates in Later-Line LBCL Therapy

1 week ago | cancernetwork.com | Tim Cortese

LYL314, an autologous dual-targeting CD19/CD20 CAR T-cell product candidate, showed robust clinical responses in the third-line or later treatment of patients with relapsed or refractory large B-cell lymphoma (LBCL) in a multicenter phase 1/2 trial (NCT05826535).
Bexobrutideg Achieves High Objective Response Rate in Heavily Pretreated R/R CLL

1 week ago | cancernetwork.com | Ashley Chan

Bexobrutideg (NX-5948), a novel BTK degrader, was generally well tolerated and demonstrated early efficacy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), according to updated data from the phase 1 NX-5948-301 trial (NCT05131022) shared at the 2025 European Hematology Association Congress. At the data cutoff date of March 12, 2025, bexobrutideg demonstrated preliminary clinical activity in a population of heavily pretreated patients with advanced CLL.
Atebimetinib Plus SOC Chemo Improves Survival, Responses in Front-Line PDAC

1 week ago | cancernetwork.com | Tim Cortese

Atebimetinib (IMM-1-104), an oral MEK inhibitor, in combination with modified gemcitabine and nab-paclitaxel (Abraxane) led to positive results, particularly regarding survival, in the frontline treatment of patients with pancreatic cancer in an ongoing phase 2a trial (NCT05585320), according to a press release from the developer, Immuneering Corporation.1 At the data cutoff of May 26, 2025, the overall survival (OS) and progression-free survival (PFS) 6-month rates were 94% (95% CI, 77%-98%)...
Olutasidenib Maintenance Shows Clinically Meaningful Activity in IDH1-Mutated AML

1 week ago | cancernetwork.com |

Results from a phase 2 trial (NCT02719574) shared at the 2025 EHA Congress showed that olutasidenib (Rezlidhia) demonstrated sustained relapse-free survival (RFS) as maintenance therapy for patients with IDH1-mutated acute myeloid leukemia (AML) who achieved complete remission (CR) or CR with incomplete hematologic recovery (CRi) following induction therapy.
Ponatinib Shows Clinical Benefit Over Imatinib in MRD-Positive Ph+ ALL Post Induction

1 week ago | cancernetwork.com | Chris Ryan

Ponatinib (Iclusig) was associated with higher rates of deep molecular responses and improved survival in patients with newly diagnosed, Philadelphia chromosome (Ph)–positive acute lymphoblastic leukemia (ALL) who were positive for minimal residual disease (MRD) after induction and continued treatment beyond cycle 3, according to findings from a post hoc analysis of the phase 3 PhALLCON trial (NCT03589326) shared at the 2025 EHA Congress.1 Data showed that 56% of patients in the ponatinib arm...